Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xcell Amnio Matrix for Diabetic Foot Ulcers
NCT07116174Recruiting
- Sponsor
- New Horizon Medical Solutions
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Injectable Hydrogels, Implantable Devices, Implantable Hydrogels
- Countries
- 1
01
Overview
Randomised trial in diabetic foot ulcer (DFU) comparing Xcell Amnio Matrix + SOC with Standard of Care (SOC) (2 arms). Primary endpoint: Proportion of subjects with complete wound closure at 12 weeks. Started Aug 2025; status: recruiting.
02
Drugs
Xcell Amnio Matrix
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT07116174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116174.